Evolving multidimensional pharmacological approaches to CNV therapy in AMD

Moshe Ehrenberg, Ofra Benny

Research output: Contribution to journalReview articlepeer-review


Purpose: The leading cause of severe visual loss world-wide is age-related macular degeneration. Although anti-Vascular Endothelial Growth Factor agents have significantly led to the initial pharmacologic reversal of vision loss in many cases of exudative macular degeneration, there still has been recurrence of choroidal neovascularization, and/or the onset of chorioretinal atrophy with fibrosis.Materials and Methods: In this review we discuss the status of anti- Vascular Endothelial Growth Factor in age-related macular degeneration and describe different studies focused on new potential therapeutic targets beyond anti- Vascular Endothelial Growth Factor.Results: Further investigations have elicited that Vascular Endothelial Growth Factor is only one of many angiogenic, and pro-inflammatory factors that bring about the growth and leakage of active choroidal neovascularization. Various new multifaceted strategies, including inhibitors to down-stream targets of endothelial cell division, such as TNP-470, may lead to a more permanent inactivation of choroidal neovascularization.Conclusions: Based on the accumulated results in the treatment of age-related macular degeneration, it is hoped that the appropriate combination of anti-Vascular Endothelial Growth Factor agents with longer-acting and multidimensional pharmaceuticals, such as Methionine Aminopeptidase-2 inhibitors, will more effectively control choroidal neovascularization, prevent atrophy and fibrosis, and reduce the burden of frequent intraocular injections in age-related macular degeneration.

Original languageAmerican English
Pages (from-to)147-154
Number of pages8
JournalCurrent Eye Research
Issue number2
StatePublished - 1 Feb 2018


  • Macular degeneration
  • VEGF
  • pathogenesis
  • review
  • therapy

All Science Journal Classification (ASJC) codes

  • Sensory Systems
  • Cellular and Molecular Neuroscience
  • Ophthalmology


Dive into the research topics of 'Evolving multidimensional pharmacological approaches to CNV therapy in AMD'. Together they form a unique fingerprint.

Cite this